Status:
COMPLETED
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.
Eligibility Criteria
Inclusion
- Age 18 years or greater
- Biopsy-proven breast malignancy
- \>/= 1 viable lesion, \>/= 1 cm, confirmed on CT, MR, or FDG PET/CT within 4 weeks of protocol enrollment
- Newly diagnosed or recurrent disease, on or off therapy
- ECOG performance of 0-2 \*Note: Lesions are considered viable if they are stable or increasing soft tissue lesions, or if they are FDG-avid bone lesions
Exclusion
- Life expectancy \< 3 months
- Pregnancy or lactation
- Biopsy or other surgical procedures within 48 hours prior to receiving study intervention
- Patients who cannot undergo PT/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 400 pounds
Key Trial Info
Start Date :
August 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04054986
Start Date
August 9 2019
End Date
September 18 2020
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065